The sellers would have picked up options at 3.75c some time ago.
There still needs to be private payers and bigger exposure away from Lymphedema to really move forward. As much as the product to measure Lymphoedema is excellent. The majority do not see this as a major market.
This is why I see Renal and Heart news as the real moving force and will need to continue in the future
Cheers
Ann: FDA Grants Breakthrough Device Designation for Renal Failure, page-12
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.001(1.79%) |
Mkt cap ! $111.2M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 5.8¢ | 5.5¢ | $47.99K | 858.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 513413 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 102335 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IPD (ASX) Chart |